Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Feb 01, 2016 10:33am

276 Views

Post# 24512135

RE:APPARANT GOOD NEWS FOR RVX NOTED BY F6

Jkj...great post.

This is precisely the kind of epigenetic momentum and credibility building that should add to the momentum of both Resverlogix and Zenith.

It is truly a shame that Resverlogix did not capitalize on the announcement of their peer reviewed article in the journal Atherosclerosis. This should have been all over the news in the health columns and business reports. Perhaps I missed it.

I couldn't read the previous article you posted because at p2 I had to sign in and was blocked.
Cheers
Toinv

Bullboard Posts

Changing Europe’s dependency on HREE from China